Vinblastine

Vinblastine has been studied in 3 papers since 2021: 1 observational study in people, 2 in animals; 2 in the past year. The newest story, Oct 29, 2026: “Drug combination limited brain tumor regrowth in mice”.

Intervention

3 papers study it4 more mention it1 findingUpdated Oct 29, 2026

PubChem MeSH

1 new paper in 30 daysSee all 7

None of its findings points the other way.

2 independent labs in 2 countries
16 trials, none about aging, 1 with no results posted

Funders: National Institutes of Health and others

Humans1
Animals2

What did lifespan studies of Vinblastine find?

DrugAge

DrugAge records 1 result from 1 paper: 1 in D. melanogaster. Average lifespan is the mean or the median, as each paper reports it.

D. melanogasterCanton-S, females, 20 μM−5.1% averagenot significant

What did studies of Vinblastine find?

Studies of Vinblastine measured 1 outcome; the most studied are cellular senescence (1 study).

Cellular senescence

upin human cells1

1 study

Vinblastine induces cellular senescence in human cells (BT-40 cells treated in vitro).
“Senescence is induced in BT-40 cells in vitro when treated not only with Trametinib, but also with Dabrafenib and Vinblastine.”
CellsBT-40 cells treated in vitro
Standard treatment against paediatric BRAF-V600E glioma promotes senescence and sensitizes tumours to BCL-xL inhibition
bioRxiv (Cold Spring Harbor Laboratory)Jan 14, 2026Preprint

Who is developing Vinblastine?

1 company: Takeda.

Companies: TakedaPhase 4Hodgkin lymphoma, Hodgkin disease

Trial sponsors

Takeda
Company3 trialsPhase 41,517 people
Merck & Co.
Company2 trialsPhase 2486 people
Seagen
Company2 trialsPhase 2306 people
Bristol Myers Squibb
Company1 trialPhase 2294 people
AstraZeneca
Company1 trialPhase 2150 people
Hope Cancer Institute
Company1 trialPhase 235 people
Roche
Company1 trialPhase 225 people
European Organisation for Research and Treatment of Cancer - EORTC
1 trialPhase 31,649 people

Latest

3 papers in 12 months

Neuro-oncologyOct 29

Drug combination limited brain tumor regrowth in mice

In mice carrying childhood brain tumor models, trametinib plus navitoclax reduced regrowth after treatment stopped and improved survival.In mice carrying childhood brain tumor models, trametinib plus navitoclax reduced regrowth after treatment stopped and improved survival.

Mouse studyInterventions